Reply to: “Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials” and “Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer”